Research in CONECT-AML is organized into five working groups (Work package or WP).

WP1 “AML predisposition and genomics” aims to:

  • Better characterize the genetic abnormalities associated with AML in children and adolescents
  • Seek new predispositions
  • Study myeloid leukemogenesis in three known predisposition contexts (congenital neutropenia, GATA2 gene mutation, Fanconi anemia)

WP2 “Modulation of the NK / CSL synapse by the pediatric AML medullary microenvironment” aims to study the interaction of the leukemic stem cell with the immediate microenvironment including mesenchymal stem cells and innate killer lymphocytes (NK cells).

WP3 “Development of faithful models of pediatric AML and therapeutic perspectives” aims to:

  • Develop new experimental models for the study of leukemic samples (in vitro culture and PDX models (Patient-derived xenograft)
  • Develop “drug-testing”, which enables to study the sensitivity of leukemic cells to new anti-cancer agents

WP4 “MET-LEA: Metabolic Syndrome in Patients Recovering from Pediatric LAM” aims to assess the impact of early management of metabolic syndrome in former patients. Indeed, some adults cured of AML in childhood may have metabolic problems (diabetes, overweight, cholesterol, hypertension) several years after recovery. MET-LEA will evaluate the efficacy of specific management of these metabolic side effects from AML treatment in recovered patients.

WP5 « IMPROVE » (Implementation, Management, Participatory Reflection, OVErview of the project) aims to:

  • Foster synergies and reflection between teams
  • Detect the most promising results and accelerate transfer to patients
  • Foster other collaborations and associated projects
  • Evaluate the ethical aspects and issues of research
  • Inform the general public